Pfizer (NYSE:PFE) Stock Price Down 0.3% – Should You Sell?

by · The Cerbat Gem

Pfizer Inc. (NYSE:PFE – Get Free Report) shares were down 0.3% on Monday . The company traded as low as $26.61 and last traded at $26.63. Approximately 10,115,846 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 37,457,648 shares. The stock had previously closed at $26.72.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PFE. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. Wells Fargo & Company boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Eight investment analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Read Our Latest Research Report on PFE

Pfizer Stock Up 2.0 %

The business has a 50 day simple moving average of $28.80 and a 200-day simple moving average of $28.68. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $151.42 billion, a price-to-earnings ratio of 35.54, a P/E/G ratio of 0.83 and a beta of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.17) earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.29%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insider Activity

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pfizer in the 1st quarter worth $315,000. GSA Capital Partners LLP purchased a new position in shares of Pfizer during the 1st quarter worth approximately $439,000. Koshinski Asset Management Inc. boosted its stake in shares of Pfizer by 20.5% in the first quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company’s stock valued at $673,000 after buying an additional 4,130 shares in the last quarter. Dearborn Partners LLC raised its position in Pfizer by 18.4% in the first quarter. Dearborn Partners LLC now owns 32,683 shares of the biopharmaceutical company’s stock worth $907,000 after acquiring an additional 5,077 shares in the last quarter. Finally, Private Management Group Inc. grew its stake in shares of Pfizer by 270.7% during the 1st quarter. Private Management Group Inc. now owns 26,579 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 19,409 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories